Lung Cancer
A Phase 2 Study to Investigate the Safety and Efficacy of Petosemtamab in Combination with Docetaxel as Second-Line Treatment in Adults with Metastatic Non-Small Cell Lung Cancer or in Combination with Pembrolizumab as First-Line Treatment (MCLA-158-CL04)
- Details
ClinicalTrials.gov ID:
NCT07353957
Diagnosis Type:
NA
USOR Number:
- Address
,
P: